Randomized Phase II Trial of Capecitabine Plus Cisplatin Versus Paclitaxel as First Line Treatment for Metastatic Esophageal Squamous Cell Carcinoma

Annals of Oncology ◽

10.1093/annonc/mdt203.59 ◽

2013 ◽

Vol 24 ◽

pp. iv53

Author(s):

Su Jin Lee ◽

Silvia Park ◽

Wonjin Chang ◽

Jung Yong Hong ◽

Moon Ki Choi ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study

10.1186/s12885-015-1716-9 ◽

2015 ◽

Vol 15 (1) ◽

Author(s):

Su Jin Lee ◽

Sungmin Kim ◽

Moonjin Kim ◽

Jeeyun Lee ◽

Yeon Hee Park ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Study ◽

Line Treatment ◽

Randomized Phase Ii ◽

First Line Treatment

Download Full-text

123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

Annals of Oncology ◽

10.1016/j.annonc.2021.10.142 ◽

2021 ◽

Vol 32 ◽

pp. S1432

Author(s):

D.A. Colevas ◽

K. Misiukiewicz ◽

A.T. Pearson ◽

J. Fayette ◽

J.R. Bauman ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

Metastatic Squamous Cell Carcinoma ◽

First Line Treatment

Download Full-text

Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5567 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5567-5567 ◽

Author(s):

J. Guigay ◽

J. Fayette ◽

A. Dillies ◽

C. Sire ◽

J. N. Kerger ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Results ◽

First Line Treatment

Download Full-text

926TiP Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1336 ◽

2021 ◽

Vol 32 ◽

pp. S814

Author(s):

G. Obara ◽

J. Sun ◽

D. Loo ◽

C. Bohac

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Neck Squamous Cell Carcinoma ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.5531 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 5531-5531 ◽

Author(s):

C. Le Tourneau ◽

E. Winquist ◽

S. J. Hotte ◽

S. A. Laurie ◽

D. Soulieres ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.5561 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 5561-5561 ◽

Author(s):

L. L. Siu ◽

S. J. Hotte ◽

S. A. Laurie ◽

S. Singh ◽

E. Winquist ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Phase Ii ◽

Squamous Cell ◽

Egf Receptor ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first‐line treatment of advanced esophageal squamous cell carcinoma

Cancer Communications ◽

10.1002/cac2.12119 ◽

2020 ◽

Vol 40 (12) ◽

pp. 711-720

Author(s):

Bo Zhang ◽

Ling Qi ◽

Xi Wang ◽

Jianping Xu ◽

Yun Liu ◽

...

Keyword(s):

Clinical Trial ◽

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Clinical Trial ◽

Line Treatment ◽

First Line Treatment

Download Full-text

66P Camrelizumab combined with paclitaxel and nedaplatin in the first-line treatment of locally advanced/advanced esophageal squamous cell carcinoma: A phase II, single-arm, exploratory research

Annals of Oncology ◽

10.1016/j.annonc.2021.10.084 ◽

2021 ◽

Vol 32 ◽

pp. S1400

Author(s):

X. Wang ◽

J. Ma ◽

J. Zhang ◽

Y. Yang ◽

D. Zheng ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Locally Advanced ◽

Exploratory Research ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.

Case Medical Research ◽

10.31525/ct1-nct04063683 ◽

2019 ◽

Author(s):

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Line Treatment ◽

First Line Treatment

Download Full-text

Randomized phase II trial comparing tumor bed alone with tumor bed and elective nodal postoperative radiotherapy in patients with locoregionally advanced thoracic esophageal squamous cell carcinoma

Diseases of the Esophagus ◽

10.1093/dote/doz013 ◽

2019 ◽

Author(s):

X-W Cai ◽

Y Zeng ◽

W Feng ◽

M-N Liu ◽

W Yu ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Esophageal Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

Postoperative Radiotherapy ◽

Tumor Bed ◽

Randomized Phase Ii

Download Full-text